Vascular Connections
The Official Newspaper of the Vascular Annual Meeting
SOCIETY FOR VASCULAR SURGERY
◆
VESS
◆
VQI
◆
VRIC
◆
AVF
◆
SVN
◆
SVU
The vasculature united: Bringing together competing specialties for better patient care By Bryan Kay Incoming Society for Vascular Surgery (SVS) President Ali AbuRahma, MD, knows the topic of this year’s E. Stanley Crawford Critical Issues Forum at the Vascular Annual Meeting (VAM) might make him as many enemies as it will friends. “You are going to find some people who will love me and some people who will hate me,” he laughs, “Because some of the surgeons on the extremes don’t want anyone to touch the vascular specialty. On the other side, many cardiologists and interventional radiologists think vascular surgeons are doing some stuff they are not qualified to do.”
B
ut AbuRahma is not dissuaded by any notion of warring tribes in the angiosuite. He picked this year’s issue quite deliberately—the role of multispecialty practice in vascular and endovascular surgery—with a burning question in mind: “Can we work together?” “The reason I picked ‘Can we work together?’ is because, presently, it’s not uncommon in many centers, hospitals and universities to find the vascular surgeon not only in competition but even in political battles with others. Specialists are fighting each other because everybody thinks they will do a better job for vascular patients,” AbuRahma tells
Ali AbuRahma
Vascular Connections in a recent interview. That’s why the lineup of the forum includes not only AbuRahma providing the vascular surgeon perspective, but also viewpoints from interventional cardiology, interventional radiology and interventional vascular medicine. From the vascular surgeon’s vantage point, the storied history of the specialty has deep roots. “The reality is vascular surgery started with our specialty, and, as you know, that’s why we are celebrating 75 years of our existence as the SVS this year,” AbuRahma explains. “Our specialty goes back a very long time in the United States. “In the last couple of decades, other specialists began to enter the field. Sometimes they are justified, sometimes they are not. Sometimes they are trained to do a great job for patient care, sometimes they are not— and that’s the reason that I felt, perhaps if I could get a session
Preview edition AUGUST 18–AUGUST 21, 2021
where we spend time and listen to one another, we could make progress.” The three other speakers who will talk during the forum each come from multispecialty practices carrying out some type of vascular or endovascular work. “Mark Bates, MD, happens to be one of my associates in my multidisciplinary group within my practice at West Virginia University School of Medicine/Charleston Area Medical Center in Charleston, West Virginia, where various specialists work together for vascular patient care, and I am the head of that group,” says AbuRahma. “He is a leader in the interventional cardiology field. “From interventional radiology, we have James F. Benenati, MD, of Miami Cardiac & Vascular Institute. He was the president of the Society of Interventional Radiology, and he will discuss that perspective and what they can do in the vascular field. And we have Bruce Gray, DO, from the University of South Carolina in Greenville, who is very well respected for interventional vascular medicine.” Each speaker will deliver a 15- to 20-minute talk after which a panel discussion with opportunities for questions and answers will take place. There is a stark backdrop to the very concept of multidisciplinary vascular care: Vascular surgeons are a relative minority in a crowded field of specialists who treat vascular disease, AbuRahma points out. “Why are we a relative minority?”, asks
“Specialists are fighting each other because everybody thinks they will do a better job for vascular patients”— ALI ABURAHMA
continued on page 2
'COVID-19 sparks diabetic macrophage inflammation' – award-winning paper By Bryan Kay When patients with diabetes are infected with coronavirus, specialized macrophage cells—already primed to develop excessive inflammation in this population—are further transformed into a pathologically inflammatory state by a decrease in the enzyme histone methyltransferase, or SETDB2, this year’s SVS Foundation Resident Research Award-winning paper reveals. RESULTS TO BE PRESENTED BY LEAD author W. James Melvin, MD, a general surgery resident at the University of Michigan in Ann Arbor, describe a potential mechanism for the increased macrophagemediated “cytokine storm” in patients with type-2 diabetes in response to COVID-19, suggesting that therapeutic targeting of an interferon-beta (IFNß) mechanism “may decrease pathologic inflammation associated with COVID-19.” The work—entitled “Coronavirus induces diabetic macrophage-mediated inflammation via IFNß regulation of SETDB2”—emerged out of the University of Michigan lab led by Melvin’s mentor on the investigation, Katherine A. Gallagher, MD. Prior to the pandemic, lab researchers had investigated why people with diabetes experience worsening wound healing in the context of peripheral arterial disease (PAD), discovering it was due in part to epigenetic changes in macrophages in the patients with diabetes. As the pandemic took hold last year, continued on page 2